Editas Medicine, Inc.
EDIT- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001650664
In the last 90 days, Editas Medicine, Inc. insiders filed 0 open-market purchases and 5 sales; 215 institutions reported holding it in 13F filings for Q2 2026, worth $386.3M in total; no superinvestor holds it.
Holders of 5% or more of EDIT
Holders whose latest Schedule 13D or 13G filing reports 5% or more of Editas Medicine, Inc., largest stake first. The change is against the holder's previous filing.
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| BlackRock, Inc. | 13G/A | 7.90%6.54M shares | – | Apr 17, 20251 filing | Apr 17, 2025 | SEC |
Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.
13D and 13G filings
3 Schedule 13D and 13G filings on Editas Medicine, Inc., newest first, including old-format filings without a stake.
| Filed (ET) | Filer | Form | Stake | Change | Event date | Filing |
|---|---|---|---|---|---|---|
| Mar 26, 20266:04 PM ET | Vanguard Group Inc | 13G/A | 0.00%0 shares | –Below 5% | Mar 13, 2026 | SEC |
| Apr 17, 20259:35 AM ET | BlackRock, Inc. | 13G/A | 7.90%6.54M shares | – | Mar 31, 2025 | SEC |
| Feb 14, 20258:45 AM ET | Deep Track Capital, LPand 2 others | 13G/A | 0.00%0 shares | –Below 5% | Dec 31, 2024 | SEC |
Form 144: proposed insider sales
Notices from officers, directors and other affiliates planning to sell Editas Medicine, Inc. shares.
No Form 144 notices for Editas Medicine, Inc. are on file.